Literature DB >> 10767339

(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features.

A M Peier1, K L McIlwain, A Kenneson, S T Warren, R Paylor, D L Nelson.   

Abstract

Fragile X syndrome is a common cause of mental retardation involving loss of expression of the FMR1 gene. The role of FMR1 remains undetermined but the protein appears to be involved in RNA metabolism. Fmr1 knockout mice exhibit a phenotype with some similarities to humans, such as macroorchidism and behavioral abnormalities. As a step toward understanding the function of FMR1 and the determination of the potential for therapeutic approaches to fragile X syndrome, yeast artificial chromosome (YAC) transgenic mice were generated in order to determine whether the Fmr1 knockout mouse phenotype could be rescued. Several transgenic lines were generated that carried the entire FMR1 locus with extensive amounts of flanking sequence. We observed that the YAC transgene supported production of the human protein (FMRP) which was present at levels 10 to 15 times that of endogenous protein and was expressed in a cell- and tissue-specific manner. Macro-orchidism was absent in knockout mice carrying the YAC transgene indicating functional rescue by the human protein. Given the complex behavioral phenotype in fragile X patients and the mild phenotype previously reported for the Fmr1 knockout mouse, we performed a more thorough evaluation of the Fmr1 knockout phenotype using additional behavioral assays that had not previously been reported for this animal model. The mouse displayed reduced anxiety-related responses with increased exploratory behavior. FMR1 YAC transgenic mice overexpressing the human protein did produce opposing behavioral responses and additional abnormal behaviors were also observed. These findings have significant implications for gene therapy for fragile X syndrome since overexpression of the gene may harbor its own phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767339     DOI: 10.1093/hmg/9.8.1145

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  106 in total

1.  Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning.

Authors:  Weixiang Guo; Andrea M Allan; Ruiting Zong; Li Zhang; Eric B Johnson; Eric G Schaller; Adeline C Murthy; Samantha L Goggin; Amelia J Eisch; Ben A Oostra; David L Nelson; Peng Jin; Xinyu Zhao
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

2.  Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.

Authors:  S M Goebel-Goody; E D Wilson-Wallis; S Royston; S M Tagliatela; J R Naegele; P J Lombroso
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

Review 3.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

4.  Comprehensive motor testing in Fmr1-KO mice exposes temporal defects in oromotor coordination.

Authors:  Snigdha Roy; Yu Zhao; Melody Allensworth; Mohamed F Farook; Mark S LeDoux; Lawrence T Reiter; Detlef H Heck
Journal:  Behav Neurosci       Date:  2011-10-17       Impact factor: 1.912

5.  Olfactory discrimination learning in mice lacking the fragile X mental retardation protein.

Authors:  John Larson; Daniel Kim; Roseanne C Patel; Christina Floreani
Journal:  Neurobiol Learn Mem       Date:  2008-03-04       Impact factor: 2.877

6.  Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome.

Authors:  Maria Isabel Carreno-Munoz; Fabienne Martins; Maria Carmen Medrano; Elisabetta Aloisi; Susanna Pietropaolo; Corentin Dechaud; Enejda Subashi; Guillaume Bony; Melanie Ginger; Abdelmalik Moujahid; Andreas Frick; Xavier Leinekugel
Journal:  Neuropsychopharmacology       Date:  2017-07-19       Impact factor: 7.853

7.  Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.

Authors:  Aimee V Franklin; Margaret K King; Valle Palomo; Ana Martinez; Lori L McMahon; Richard S Jope
Journal:  Biol Psychiatry       Date:  2013-09-13       Impact factor: 13.382

8.  Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring.

Authors:  Bojana Zupan; Miklos Toth
Journal:  J Pharmacol Exp Ther       Date:  2008-09-23       Impact factor: 4.030

Review 9.  The role of ARID1B, a BAF chromatin remodeling complex subunit, in neural development and behavior.

Authors:  Jeffrey J Moffat; Eui-Man Jung; Minhan Ka; Amanda L Smith; Byeong Tak Jeon; Gijs W E Santen; Woo-Yang Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-08-24       Impact factor: 5.067

Review 10.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.